Having trouble accessing articles? Reset your cache.

Analyst picks & changes

Analyst picks & changes

Company Bank Analyst Coverage Opinion Wk chg 8/6 cls
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Leerink Joseph Schwartz Price target Market outperform -1% $21.54
Summer Street Carol Werther Price target Buy
Schwartz lowered his target to $25 from $27 after BioMarin reported lower 2Q10 sales and higher SG&A than anticipated. The company reported 2Q10 revenue of $92M, missing his and the Street's estimates $97.8M and $95.1M, respectively. BioMarin also lowered its FY10 revenue guidance to $370-$393M from $374-$405M. Schwartz reduced his FY10 and FY11 revenue estimates to $377.2M and $442M, respectively, from $391.6M and $458.2M. He also

Read the full 1203 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers